Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer
Small-cell lung cancer is a highly aggressive form of lung cancer that accounts for approximately 13–15% of all lung cancer cases1 and is strongly linked to tobacco exposure. Despite existing treatments, SCLC has a high recurrence rate and is associated with poor overall prognosis. While improvements in overall survival are occurring with newer therapies, most patients experience rapid disease progression2.
"The Orphan Drug Designation from the FDA underscores both the seriousness of small cell lung cancer and the lack of effective treatment options," said Michael C. Cox, PharmD, MHSc, BCOP, SVP, and head of early development Circle Pharma. "We are committed to accelerating the clinical development of CID-078 to offer new hope for patients who face limited therapeutic choices."
The FDA's Orphan Drug Designation program is intended to promote the development of drugs for rare diseases or conditions affecting fewer than 200,000 people in the United States3. This designation provides several development incentives, including seven years of market exclusivity upon regulatory approval, tax credits for qualified clinical trial costs, and eligibility to apply for FDA-administered research grants4.
Circle Pharma has initiated a Phase 1 clinical trial (NCT06577987) of CID-078 to evaluate its safety, tolerability, pharmacokinetics, and early signs of anti-tumor activity in patients with advanced solid tumors, including SCLC.
About CID-078, Circle Pharma's Cyclin A/B RxL Inhibitor Program
CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation. In biochemical and cellular studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and Myt1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center phase 1 clinical trial (NCT06577987) is currently enrolling patients.
About Circle Pharma, Inc.
South San Francisco-based Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. Its lead program, CID-078, a cyclin A/B-RxL inhibitor, is in a Phase 1 clinical trial (NCT06577987) for patients with advanced solid tumors.
To learn more about Circle Pharma, please visit www.circlepharma.com.
American Cancer Society. What is Small Cell Lung Cancer? https://www.cancer.org/cancer/lung-cancer/about/what-is.html
National Cancer Institute. Small Cell Lung Cancer Treatment (PDQ®)–Patient Version. https://www.cancer.gov/types/lung/patient/small-cell-lung-treatment-pdq
U.S. Food and Drug Administration. Developing Products for Rare Diseases & Conditions. https://www.fda.gov/industry/developing-products-rare-diseases-conditions
U.S. Food and Drug Administration. Benefits of Orphan Drug Designation. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products
View source version on businesswire.com: https://www.businesswire.com/news/home/20250616163110/en/
Contacts
Media Contact: Roslyn PattersonPhone: 650.825.4099Email: roslyn.patterson@circlepharma.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Are We in a Crypto Bubble?
Market bubbles can form when macroeconomic and industry trends combine. Cryptocurrency's last big bubble was in 2021. It is reasonable to wonder whether crypto is in a bubble right now. 10 stocks we like better than Bitcoin › Markets love a juicy narrative, and "crypto bubble 2.0" is certainly juicy. Bitcoin (CRYPTO: BTC) sits near $117,000, only a whisker from its all-time high set July 10, while big altcoins, such as Solana (CRYPTO: SOL), Ethereum (CRYPTO: ETH), and XRP (CRYPTO: XRP), have doubled or better since mid-2023. Yet bubble talk is cheap. History punishes investors who sell first and ask questions later, so it pays to look under the hood before slapping the B-word on today's rally. Let's unpack why prices are higher, why the mood is nothing like the euphoria of 2021, and what that means for long-term investors. If you pay careful attention here, it just might save you from timing mistakes that haunt your portfolio for years. A bubble, by definition, is a price divorced from fundamentals. That diagnosis is tricky in crypto because fundamentals evolve fast, but a few data points stand out. First, demand in the sector is now predominantly institutional, not retail. U.S. spot Bitcoin exchange-traded funds (ETFs) have sucked in roughly $50 billion since launching 18 months ago. Those coins are locked away in cold storage for a steady trickle of staking fee income, which is hardly the stuff of manic speculation. Second, the macro backdrop is set to improve rather than worsen. The Federal Reserve held its benchmark interest rate steady in June but penciled in two cuts before the end of the year, with potentially more to follow in 2026. Looser monetary policy historically expands the money supply and the risk appetite, which is exactly what happened during the last big crypto bubble in 2021. If cuts arrive on schedule, crypto could enjoy a liquidity tailwind that was absent during 2022's wipeout. Third, utility on leading chains is finally visible, which is to say there's a concrete reason to buy the native tokens of those chains. Solana's weekly network fees and its application revenue are surging to new highs -- people are using its decentralized finance (DeFi) applications, and platform operators are generating money as a result. XRP's ledger, meanwhile, is onboarding tokenized U.S. Treasuries and bank-friendly compliance tools, making it a more attractive home for institutional capital. That fee and transaction revenue is small in absolute terms, but it proves that these coins are being bought to pave the way for real workloads, not just speculation. Separately from the above, one thing that people tend to be curious about is how meme coins fit into the picture. Yes, meme coins exist, and they still spike to silly valuations of $1 billion or more. However, the entire meme coin cohort is currently valued at only $64.1 billion, just a smidgen of crypto's $3.7 trillion total market capitalization. And it isn't as though new meme stars are emerging every day in a way that captures attention outside of the limited circles of crypto insiders. When the market is at its euphoric peaks, there are many tell-tale signs, ranging from soaring retail inflows to sky-high use of leverage and nearly incessant dinner table chatter from people who don't usually invest. None of those are flashing red today. Start with sentiment. The Crypto Fear & Greed Index, offered by CoinMarketCap, reads 67 ("greed"), well below the 90-plus extremes logged in early 2021 and late 2024. Greed is in control at this moment, yes, but it's hardly mania by historical standards. Web search interest tells a similar story. Searches for "Bitcoin" remain near six-month lows even as its price grinds higher, indicating that newcomers are not piling in en masse. Other signals, like the app store ranking of crypto wallet and trading apps, also look ice cold. On-chain data is equally sober. Glassnode, a crypto data provider, calculates that a "super majority" of holders sit on unrealized profits after Bitcoin's rebound past $107,000. This implies that there could be some profit-taking in store, but also that almost nobody is under pressure to sell. Furthermore, leverage in derivatives markets sits well below 2021 peaks. The odds of a liquidation spiral sending the price downward are low. Could sentiment overheat relatively soon? Absolutely. The macroeconomic tailwinds look quite favorable for the entire crypto sector right now, as does government policy, and as does monetary policy in the near term. And with institutional capital piling in, a lot could happen to ignite super-positive sentiment as soon as this fall. But for now, no crypto traders are flashing their newly purchased Lamborghinis on social media. Nor are the valuations of most of the crypto majors overextended compared to 2021. So, don't get scared out of the market by talk of a bubble. In sum, the data indicates that we are in a warm but far from overheated market. Keep an eye on the key indicators so that you will be ahead of the game if they start to signal too much froth. Before you buy stock in Bitcoin, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Bitcoin wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Alex Carchidi has positions in Bitcoin, Ethereum, and Solana. The Motley Fool has positions in and recommends Bitcoin, Ethereum, Solana, and XRP. The Motley Fool has a disclosure policy. Are We in a Crypto Bubble? was originally published by The Motley Fool
Yahoo
14 minutes ago
- Yahoo
If You're Not Doing This One Thing, You May Not Be Pooping Correctly
Among the current wave of wellness obsessions, fibermaxxing is gaining major traction. This more-is-more approach to fiber is touted on TikTok as a way to boost digestion, satiety and overall gut health while also addressing the fact that most Americans aren't getting enough. But while increasing your fiber intake has clear benefits, nutrition experts say there's a right way to do it if you want to see results. Related: What is fibermaxxing? The TikTok trend is all about maximizing fiber intake by loading up every meal and snack with fiber-rich foods, and sometimes supplements, to support gut health, satiety, cholesterol levels, blood sugar stability and even cancer prevention. It reflects a growing shift away from protein-obsessed diets toward a stronger focus on digestive and colon health. But Jennifer House, a registered dietitian and owner of First Step Nutrition in Calgary, Alberta, cautions that if you have IBS or an inflammatory bowel condition like Crohn's disease or ulcerative colitis, a high-fiber diet might not be ideal. 'And if you suffer from constipation, increasing fiber all at once could temporarily make the situation worse.' How much fiber do we actually need? Related: For women ages 18 to 50, the general recommendation is 25 grams of fiber per day, and 21 grams for those 51 and older, House said. For men, it's 30 grams daily. 'Most people only get about half of the recommended amount of fiber each day,' she added. Fiber is found only in plant-based foods, and there are five main groups that provide it: vegetables, fruits, legumes, whole grains, and nuts and seeds. Of these, legumes pack the biggest punch. Just one cup of beans contains 10 to 19 grams of fiber, which can get you more than halfway to your daily target. 'Animal foods don't contain fiber, so an eating pattern that's disproportionately high in meat, dairy and eggs is more likely to fall short on fiber,' said registered dietitian Avery Zenker. The health benefits of fiber: Related: Fiber supports healthy digestion, helps regulate blood sugar and cholesterol levels, and promotes a sense of fullness that can aid in appetite and weight management. It's also linked to a lower risk of heart disease, type 2 diabetes and certain cancers, including colorectal and colon, Zenker noted. 'Low fiber diets are linked to microbiome imbalances and lower microbial diversity, both of which are associated with increased risk of inflammatory diseases.' Different types of fiber offer different benefits. 'Soluble fiber helps regulate blood sugar and lower cholesterol — great for patients with diabetes or heart disease risk,' said Dr. Michael Ednie, founder of Bespoke Concierge MD based in Scottsdale, Arizona. This type of fiber dissolves in water to form a gel that helps lower cholesterol and regulate blood sugar. 'Insoluble fiber promotes regularity and helps prevent constipation, which is crucial for colon health,' Ednie said. Then there's prebiotic fiber, which serves as food for the beneficial bacteria in your gut. 'As those bacteria ferment prebiotic fibers, they produce short-chain fatty acids like butyrate, which have anti-inflammatory effects and support gut barrier function. Prebiotics have also been linked to improved mineral absorption and even mood regulation via the gut-brain connection,' Ednie said. Garlic, onions, bananas and asparagus are all excellent sources. Just like variety in your overall diet supports better nutrition, eating different types of fiber helps build a healthier, more resilient gut microbiome. 'Different fibers feed different strains of beneficial bacteria, which leads to better gut health, stronger immune function and lower inflammation overall,' Ednie explained. While there's no strict formula for how much of each fiber type you need, he suggests aiming for about two-thirds insoluble fiber and one-third soluble fiber. Fibermaxxing can backfire on your digestive system. While there's no official upper limit for fiber intake, increasing it too quickly can cause gas, bloating and other digestive issues like cramping, constipation and diarrhea. 'The gut bacteria essentially go into overdrive trying to process the sudden influx of fiber, producing excess gas as a byproduct,' Ednie explained. 'In rare cases, if someone dramatically increases fiber without proper hydration or pacing, it can even lead to intestinal blockages that require medical attention.' The type of fiber you're increasing also affects the symptoms you may experience. 'Soluble fiber — found in foods like oats, apples and beans — tends to be gentler at first but often causes more gas because it's fermented by gut bacteria,' Ednie said. 'Insoluble fiber — from whole grains, vegetable skins and nuts — adds bulk and moves things along but can lead to more bloating and cramping if increased too quickly without enough water.' Zenker also notes that for some people, especially older adults and young children, the satiating effect of fiber may reduce overall food intake, potentially leading to unintended weight loss or nutrient gaps. Additionally, consuming too much fiber can interfere with the absorption of important minerals like iron, zinc and calcium by binding to them in the gut and preventing their absorption. Increasing your fluid intake is key. Related: Hydration is essential when increasing fiber intake to help it do its job effectively. 'Soluble fiber needs water to form the gel that helps regulate blood sugar and cholesterol,' Ednie explained. 'Insoluble fiber needs water to add bulk and move stool efficiently through the digestive tract.' He recommends aiming for at least eight to 10 cups of water a day when boosting your fiber intake, and more if you're active or in a hot climate, and pairing every fiber-rich meal or snack with a full glass of water to support digestion. How to safely increase your fiber intake. Nutrition experts agree that it's important to increase fiber gradually to give your digestive system time to adjust and minimize the risk of bloating or discomfort. 'Instead of jumping from 10 grams a day to 30 overnight, add just 3 to 5 grams of fiber per week,' Ednie said. He also recommends spreading your fiber intake throughout the day, like enjoying oatmeal with berries in the morning, veggies or legumes at lunch and dinner, and snacks like fruit with nuts or popcorn in between. 'Consistency makes it much easier for the body to adapt and helps create sustainable habits that support long-term gut health,' he added. Ednie also emphasizes prioritizing whole foods as your main fiber source to support digestive, metabolic and cardiovascular health. These foods naturally contain a mix of soluble and insoluble fiber, along with vitamins, minerals and phytonutrients that fiber supplements don't offer. 'Supplements can be helpful for people who struggle to meet their fiber needs through diet alone, but they should be viewed as an addition, not a replacement,' he article originally appeared on HuffPost. Also in Goodful: Also in Goodful: Also in Goodful:
Yahoo
17 minutes ago
- Yahoo
Amazon (AMZN)'s AI Push Could Fuel AWS Growth—And Wall Street Is Finally Noticing
Inc. (NASDAQ:) is one of the . On July 10, Citizens JMP analyst Andrew Boone raised the price target on the stock to $285.00 (from $250.00) while maintaining a 'Market Outperform' rating. Firm analysts are of the view that Amazon's AWS opportunity remains underappreciated. 'With reach across 100M + U.S. households, supported by a best-in-class logistics network, and ever-widening selection, we believe Amazon's ability to offer ever faster delivery can continue to unlock demand for additional retail categories and retail growth. "This retail network fuels Amazon's consumer data which is a key driver of its advertising business that we believe can continue to take share given Amazon's growing CTV business. Last, and maybe most important, we believe AI is a key driver of digital transformation and that AI can help drive AWS growth to accelerate, as the AWS opportunity remains underappreciated, in our view.' Inc. (NASDAQ:AMZN) is an American technology company offering e-commerce, cloud computing, and other services, including digital streaming and artificial intelligence solutions. While we acknowledge the potential of AMZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
